<VariationArchive VariationID="655856" VariationName="NM_000314.8(PTEN):c.469dup (p.Glu157fs)" VariationType="Duplication" Accession="VCV000655856" Version="8" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-02-14" DateCreated="2019-08-14" MostRecentSubmission="2024-02-14">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="639274" VariationID="655856">
      <GeneList>
        <Gene Symbol="PTEN" FullName="phosphatase and tensin homolog" GeneID="5728" HGNC_ID="HGNC:9588" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>10q23.31</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="10" Accession="NC_000010.11" start="87863625" stop="87971930" display_start="87863625" display_stop="87971930" Strand="+" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="10" Accession="NW_013171807.1" start="79449" stop="187719" display_start="79449" display_stop="187719" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="10" Accession="NC_000010.10" start="89623194" stop="89728531" display_start="89623194" display_stop="89728531" Strand="+" />
          </Location>
          <OMIM>601728</OMIM>
          <Haploinsufficiency last_evaluated="2020-06-24" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=PTEN">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-06-24" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=PTEN">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000314.8(PTEN):c.469dup (p.Glu157fs)</Name>
      <CanonicalSPDI>NC_000010.11:87933224:GGGG:GGGGG</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>10q23.31</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="10" Accession="NC_000010.11" start="87933224" stop="87933225" display_start="87933224" display_stop="87933225" variantLength="1" positionVCF="87933224" referenceAlleleVCF="T" alternateAlleleVCF="TG" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="10" Accession="NC_000010.10" start="89692981" stop="89692982" display_start="89692981" display_stop="89692982" variantLength="1" positionVCF="89692981" referenceAlleleVCF="T" alternateAlleleVCF="TG" />
      </Location>
      <ProteinChange>E157fs</ProteinChange>
      <ProteinChange>E330fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000314.4" sequenceAccession="NM_000314" sequenceVersion="4" change="c.469dup">
            <Expression>NM_000314.4:c.469dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000010.10" sequenceAccession="NC_000010" sequenceVersion="10" change="g.89692985dup" Assembly="GRCh37">
            <Expression>NC_000010.10:g.89692985dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000010.11" sequenceAccession="NC_000010" sequenceVersion="11" change="g.87933228dup" Assembly="GRCh38">
            <Expression>NC_000010.11:g.87933228dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007466.2" sequenceAccession="NG_007466" sequenceVersion="2" change="g.74790dup">
            <Expression>NG_007466.2:g.74790dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000314.8" sequenceAccession="NM_000314" sequenceVersion="8" change="c.469dup" MANESelect="true">
            <Expression>NM_000314.8:c.469dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000305.3" sequenceAccession="NP_000305" sequenceVersion="3" change="p.Glu157fs">
            <Expression>NP_000305.3:p.Glu157fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001304717.5" sequenceAccession="NM_001304717" sequenceVersion="5" change="c.988dup">
            <Expression>NM_001304717.5:c.988dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001291646.4" sequenceAccession="NP_001291646" sequenceVersion="4" change="p.Glu330fs">
            <Expression>NP_001291646.4:p.Glu330fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001304718.2" sequenceAccession="NM_001304718" sequenceVersion="2" change="c.-282dup">
            <Expression>NM_001304718.2:c.-282dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001623" Type="5 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_311" sequenceAccession="LRG_311">
            <Expression>LRG_311:g.74790dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_311t1" sequenceAccession="LRG_311t1">
            <Expression>LRG_311t1:c.469dup</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="1554898210" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000314.8(PTEN):c.469dup (p.Glu157fs) AND PTEN hamartoma tumor syndrome" Accession="RCV000812120" Version="6">
        <ClassifiedConditionList TraitSetID="2131">
          <ClassifiedCondition DB="MedGen" ID="C1959582">PTEN hamartoma tumor syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-05-11" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000314.8(PTEN):c.469dup (p.Glu157fs) AND Cowden syndrome 1" Accession="RCV003453705" Version="1">
        <ClassifiedConditionList TraitSetID="2119">
          <ClassifiedCondition DB="MedGen" ID="CN072330">Cowden syndrome 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-09-28" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-09-28" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2019-08-14" MostRecentSubmission="2024-02-14">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">21194675</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9467011</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="2119" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="13756" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Cowden syndrome 1</ElementValue>
                <XRef ID="MONDO:0008021" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">MHAM</ElementValue>
                <XRef Type="MIM" ID="158350" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">CWS1</ElementValue>
                <XRef Type="MIM" ID="158350" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">The PTEN hamartoma tumor syndrome (PHTS) includes Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS), PTEN-related Proteus syndrome (PS), and PTEN-related Proteus-like syndrome. CS is a multiple hamartoma syndrome with a high risk for benign and malignant tumors of the thyroid, breast, kidney, and endometrium. Affected individuals usually have macrocephaly, trichilemmomas, and papillomatous papules, and present by the late 20s. The lifetime risk of developing breast cancer is 85%, with an average age of diagnosis between 38 and 46 years. The lifetime risk for thyroid cancer (usually follicular, rarely papillary, but never medullary thyroid cancer) is approximately 35%. The lifetime risk for renal cell cancer (predominantly of papillary histology) is 34%. The risk for endometrial cancer may approach 28%. BRRS is a congenital disorder characterized by macrocephaly, intestinal hamartomatous polyposis, lipomas, and pigmented macules of the glans penis. PS is a complex, highly variable disorder involving congenital malformations and hamartomatous overgrowth of multiple tissues, as well as connective tissue nevi, epidermal nevi, and hyperostoses. Proteus-like syndrome is undefined but refers to individuals with significant clinical features of PS who do not meet the diagnostic criteria for PS.</Attribute>
                <XRef ID="NBK1488" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="274">gain of function</Attribute>
                <XRef ID="GTR000528377" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000514929" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520872" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522278" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528059" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528912" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528914" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000556509" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592450" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509012" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509038" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000514990" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552183" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520030" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520869" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520871" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528910" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000553541" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="16450" />
                <XRef ID="16450" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301661</ID>
                <ID Source="BookShelf">NBK1488</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2008">
                <ID Source="pmc">3111012</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <XRef ID="CN072330" DB="MedGen" />
              <XRef ID="MONDO:0008021" DB="MONDO" />
              <XRef Type="MIM" ID="158350" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="2131" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="10363" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">PTEN Hamartomatous Tumour Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">PTEN hamartoma tumor syndrome</ElementValue>
                <XRef ID="MONDO:0017623" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">PTEN-related disorders</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">PHTS</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="12800" />
                <XRef ID="12800" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000326160" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552440" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000595970" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551654" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552184" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552245" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552302" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558905" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558503" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">The PTEN hamartoma tumor syndrome (PHTS) includes Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS), PTEN-related Proteus syndrome (PS), and PTEN-related Proteus-like syndrome. CS is a multiple hamartoma syndrome with a high risk for benign and malignant tumors of the thyroid, breast, kidney, and endometrium. Affected individuals usually have macrocephaly, trichilemmomas, and papillomatous papules, and present by the late 20s. The lifetime risk of developing breast cancer is 85%, with an average age of diagnosis between 38 and 46 years. The lifetime risk for thyroid cancer (usually follicular, rarely papillary, but never medullary thyroid cancer) is approximately 35%. The lifetime risk for renal cell cancer (predominantly of papillary histology) is 34%. The risk for endometrial cancer may approach 28%. BRRS is a congenital disorder characterized by macrocephaly, intestinal hamartomatous polyposis, lipomas, and pigmented macules of the glans penis. PS is a complex, highly variable disorder involving congenital malformations and hamartomatous overgrowth of multiple tissues, as well as connective tissue nevi, epidermal nevi, and hyperostoses. Proteus-like syndrome is undefined but refers to individuals with significant clinical features of PS who do not meet the diagnostic criteria for PS.</Attribute>
                <XRef ID="NBK1488" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301661</ID>
                <ID Source="BookShelf">NBK1488</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACS, 2007">
                <ID Source="PubMed">17392385</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23519317</ID>
              </Citation>
              <Citation Type="general" Abbrev="NCCN, 2014">
                <ID Source="PubMed">25190698</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACG, 2015">
                <ID Source="PubMed">25645574</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Skin Cancer">
                <ID Source="PubMed">26389333</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Genetics of Colorectal Cancer">
                <ID Source="PubMed">26389505</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <XRef ID="306498" DB="Orphanet" />
              <XRef ID="C1959582" DB="MedGen" />
              <XRef ID="D006223" DB="MeSH" />
              <XRef ID="MONDO:0017623" DB="MONDO" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1846557" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2019-08-14">
        <ClinVarSubmissionID localKey="4886373|MedGen:C1959582" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000952424" DateUpdated="2024-02-14" DateCreated="2019-08-14" Type="SCV" Version="6" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-05-11">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">9467011</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21194675</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Glu157Glyfs*23) in the PTEN gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in PTEN are known to be pathogenic (PMID: 9467011, 21194675). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with PTEN-related conditions. ClinVar contains an entry for this variant (Variation ID: 655856). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PTEN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000010.10:g.89692981_89692982insG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1959582" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7828969" SubmissionDate="2023-12-21" DateLastUpdated="2023-12-24" DateCreated="2023-12-24">
        <ClinVarSubmissionID localKey="100647310|OMIM:158350" />
        <ClinVarAccession Accession="SCV004188896" DateUpdated="2023-12-24" DateCreated="2023-12-24" Type="SCV" Version="1" SubmitterName="Myriad Genetics, Inc." OrgID="507240" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-09-28">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Myriad Autosomal Dominant, Autosomal Recessive and X-Linked Classification Criteria (2023)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/8ufcwsf2/myriad_genetics_classification_criteria_2023.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PTEN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="hg19" Chr="10" alternateAllele="GG" referenceAllele="G" start="89692985" stop="89692985" />
          </Location>
          <OtherNameList>
            <Name Type="SubmitterVariantId">100647310</Name>
          </OtherNameList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="158350" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14104645</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="7828969" TraitType="Disease" MappingType="XRef" MappingValue="158350" MappingRef="OMIM">
        <MedGen CUI="CN072330" Name="Cowden syndrome 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1846557" TraitType="Disease" MappingType="XRef" MappingValue="C1959582" MappingRef="MedGen">
        <MedGen CUI="C1959582" Name="PTEN hamartoma tumor syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

